Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.68 |
| ▸ | CA2 | P00918 | 9/20 | 0.68 |
| ▸ | CA9 | Q16790 | 9/20 | 0.68 |
| ▸ | CA12 | O43570 | 6/20 | 0.68 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16525362 | 0.93 | CA1 (0.64) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL14754541 | 0.91 | CA1 (0.67) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL19455756 | 0.90 | CA1 (0.64) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL17245254 | 0.90 | CA1 (0.64) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL22855043 | 0.89 | CA1 (0.70) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL19426705 | 0.89 | CA9 (0.71) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL23027406 | 0.88 | CA1 (0.68) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL21183301 | 0.88 | CA1 (0.70) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL21282083 | 0.88 | CA1 (0.70) | CA1CA2CA9CA12FKBP1A | |
| SCHEMBL17245251 | 0.88 | CA1 (0.70) | CA1CA2CA9CA12FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779602-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | CA1 829/4885CA2 2378/4885CA9 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.